Clarke, EGC. The identification of some proscribed psychedelic drugs J. Forensic Sci. Soc., 1 Jan 1967, 7 (1), 46-50. 336 kB. https://doi.org/10.1016/S0015-7368(67)70370-9 TLC
Wacker, D; Wang, S; McCorvy, JD; Betz, RM; Venkatakrishnan, AJ; Levit, A; Lansu, K; Schools, ZL; Che, T; Nichols, DE; Shoichet, BK; Dror, RO; Roth, BL. Crystal Structure of an LSD-Bound Human Serotonin Receptor Cell, 26 Jan 2017, 168 (3), 377–389.e12. 5.4 MB. https://doi.org/10.1016/j.cell.2016.12.033
López-Giménez, JF; González-Maeso, J. Hallucinogens and serotonin 5-HT2A receptor-mediated signaling pathways In Behavioral Neurobiology of Psychedelic Drugs; Halberstadt, AL; Vollenweider, FX; Nichols, DE, Eds., Springer, 1 Jan 2017; pp 45-73. 712 kB. https://doi.org/10.1007/7854_2017_478
Jakubczyk, D; Cheng, JZ; O'Connor, SE. Biosynthesis of the ergot alkaloids Nat. Prod. Rep., 28 Aug 2014, 31 (10), 1328-1338. 476 kB. https://doi.org/10.1039/C4NP00062E #5
Helm, K. Synthese und funktionelle In-vitro-Pharmakologie neuer Liganden des 5-HT2A-Rezeptors aus der Klasse Ph. D. Thesis, Universität Regensburg, Dresden, 1 Jan 2014. 3.2 MB. #43,53 LC,MS,NMR,IR
Peng, Y; McCorvy, JD; Harpsøe, K; Lansu, K; Yuan, S; Popov, P; Liu, Z. 5-HT2C receptor structures reveal the structural basis of GPCR polypharmacology Cell, 1 Feb 2018, 172 (4), 719-730.e14. 6.6 MB. https://doi.org/10.1016/j.cell.2018.01.001
Shulgin, AT. Basic Pharmacology and Effects In Hallucinogens. A Forensic Drug Handbook; Laing, R; Siegel, JA, Eds., Academic Press, London, 24 Apr 2003; pp 67–137. 6.3 MB.
Chambers, SA; DeSousa, JM; Huseman, ED; Townsend, SD. The DARK side of total synthesis: Strategies and tactics in psychoactive drug production ACS Chem. Neurosci., 17 Oct 2018, 9 (10), 2307–2330. 8.1 MB. https://doi.org/10.1021/acschemneuro.7b00528 #171
Gõrnemann, T; Jähnichen, S; Schurad, B; Latté, KP; Horowski, R; Tack, J; Flieger, M; Pertz, HH. Pharmacological properties of a wide array of ergolines at functional alpha1-adrenoceptor subtypes N-S. Arch. Pharmacol., 1 Jan 2008, 376 (5), 321–330. 303 kB. https://doi.org/10.1007/s00210-007-0221-3 #Ergotamine
Clancy, L; Philp, M; Shimmon, R; Fu, S. Development and validation of a color spot test method for the presumptive detection of 25-NBOMe compounds Drug Test. Anal., 19 Aug 2020, 13 (5), 929-943. 11.3 MB. https://doi.org/10.1002/dta.2905 #Ergotamine spot
Cumming, P; Scheidegger, M; Dornbierer, D; Palner, M; Quednow, BB; Martin-Soelch, C. Molecular and functional imaging studies of psychedelic drug action in animals and humans Molecules, 1 Jan 2021, 26 (9), 2451. 3.5 MB. https://doi.org/10.3390/molecules26092451 #22
Mesley, RJ; Evans, WH. Infrared identification of lysergide (LSD) J. Pharm. Pharmacol., 1 Nov 1969, 21 (11), 713–720. 484 kB. https://doi.org/10.1111/j.2042-7158.1969.tb08160.x #Ergotamine IR
Yu, A. Indolealkylamines: Biotransformations and potential drug-drug interactions AAPS J., 1 Jun 2008, 10 (2), 242–253. 314 kB. https://doi.org/10.1208/s12248-008-9028-5 #Ergotamine